Figure 2 from ORIC-101, a Glucocorticoid Receptor Antagonist, in Combination with Nab-Paclitaxel in Patients with Advanced Solid Tumors

Study disposition flow diagram of patient disposition. Note: int, intermittent regimen of ORIC-101 administered 5 days on, 2 days off for 21 days out of 28-day cycles; cont, continuous regimen of ORIC-101 administered for 21 days out of 28-day cycles; AE, adverse event; clin, clinical; OST, other solid tumors; PD, progressive disease; radiog, radiographic.